Intellia Therapeutics Rallies After FDA Lifts Clinical Hold on Key Phase 3 Trial

Shares of Intellia Therapeutics (NASDAQ: NTLA) surged 20% after the U.S. Food and Drug Administration lifted a clinical hold on the company’s Phase 3 MAGNITUDE-2 trial, easing a major regulatory overhang and restoring momentum to one of the most closely watched programs in the gene-editing space.

The FDA decision allows Intellia to resume patient enrollment and dosing in the late-stage study evaluating nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare and progressive genetic disease with limited treatment options.

Regulatory Clarity Drives Investor Confidence

The clinical hold, imposed in late 2025, followed a safety event in a related ATTR cardiomyopathy trial. While that cardiomyopathy study remains on hold, the FDA’s clearance of MAGNITUDE-2 signals regulatory confidence in the revised trial design, which includes enhanced liver safety monitoring and an expanded patient population.

For investors, the move represents a meaningful de-risking event. The ability to restart a Phase 3 program not only brings Intellia back onto a clinical timeline, but also reopens the pathway to potential registrational data — a critical value driver for clinical-stage biotech companies.

Market Reaction Reflects Catalyst Relief

NTLA shares jumped sharply on the news as investors priced out near-term downside tied to regulatory uncertainty. The rally follows weeks of pressure on the stock, highlighting how quickly sentiment can shift in gene-editing equities when binary risks are removed.

While volatility remains a defining feature of the sector, the response underscores how regulatory clarity — even partial — can act as a powerful catalyst for re-rating.

What Investors Should Watch Next

Despite the positive development, the broader ATTR program remains mixed. The ongoing FDA review of the cardiomyopathy trial will be a key swing factor for the long-term valuation of Intellia’s ATTR franchise. Any updates on timelines, protocol adjustments, or data expectations could meaningfully impact sentiment.

In the near term, investors will be focused on:

• Re-enrollment progress and trial execution in MAGNITUDE-2
• Additional regulatory communication around the cardiomyopathy study
• Broader read-throughs for CRISPR-based in vivo gene-editing platforms

Bottom Line

The FDA’s decision to lift the clinical hold on Intellia’s Phase 3 MAGNITUDE-2 trial marks a clear step forward for the company and removes a significant near-term risk from the investment narrative. While execution and regulatory uncertainties remain, the development restores credibility to Intellia’s lead program and repositions NTLA as a catalyst-driven biotech name with renewed upside — and continued volatility — ahead.